Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 20, 2015

View Archived Issues

Cempra reports topline phase III data for intravenous solithromycin

Novel polymyxin derivatives show antibacterial activity

Sunshine Lake Pharma reports anti-HBV agents

Radiolabeled G-02113 may be useful for in vivo imaging of sst receptor-expressing tumors

PharmaCyte outlines plans for upcoming pancreatic cancer trial of Cell-in-a-Box + ifosfamide

Medifocus in license agreement with Duke for heat-activated and tumor-targeted immunotherapy

Alnylam describes a more potent RNAi agent targeting transthyretin for treating amyloidosis

Profiling of novel inhibitors of bacterial topoisomerases

Avalanche Biotechnologies reports 1-year follow up from phase I trial of rAAV.sFLT-1

Agios Pharmaceuticals provides pipeline update

Kowa files for approval of pemafibrate in Japan

Genocea reports topline results from phase IIa trial of universal Pneumococcal vaccine

Addyi launched in the U.S. for generalized hypoactive sexual desire disorder

Allergan completes acquisition of AqueSys

Novel JAK3 inhibitor shows promise for Th2-driven diseases

European Commission approves isavuconazole for invasive aspergillosis and mucormycosis

Roche discloses CB2 inverse agonists

Syros Pharmaceuticals patents CDK7 inhibitors

Instytut Farmaceutyczny reports antineoplastic agents

Calitor Sciences presents protein kinase inhibitors

Orion presents TRPA1 antagonists

Inotuzumab ozogamicin receives FDA breakthrough therapy designation for ALL

CFTR amplifiers enhance the effect of CFTR modulators

La Jolla Pharmaceutical starts phase I trial of hepcidin formulation LJPC-401

Avedro resubmits NDA for corneal cross-linking system

GenKyoTex's GKT-137831 granted U.S. orphan status for systemic sclerosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...